A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

A Phase 3b/4, Multi-Center, Double-Blind, Randomized, Parallel Group Study of Tofacitinib (CP-690,550) in Subjects With Ulcerative Colitis in Stable Remission

Category & Conditions:
Immune System Diseases and Conditions
Medicine:
XELJANZ®(TOFACITINIB)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
A3921288
Open Plain Language Summary Result:Click here